These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Atkins HL; Bowman M; Allan D; Anstee G; Arnold DL; Bar-Or A; Bence-Bruckler I; Birch P; Bredeson C; Chen J; Fergusson D; Halpenny M; Hamelin L; Huebsch L; Hutton B; Laneuville P; Lapierre Y; Lee H; Martin L; McDiarmid S; O'Connor P; Ramsay T; Sabloff M; Walker L; Freedman MS Lancet; 2016 Aug; 388(10044):576-85. PubMed ID: 27291994 [TBL] [Abstract][Full Text] [Related]
7. Autologous hematopoietic stem cell transplantation in combination with immunoablative protocol in secondary progressive multiple sclerosis--A 10-year follow-up of the first transplanted patient. Obradović D; Tukić L; Radovinović-Tasić S; Petrović B; Elez M; Ostojić G; Balint B Vojnosanit Pregl; 2016 May; 73(5):504-8. PubMed ID: 27430119 [TBL] [Abstract][Full Text] [Related]
8. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548 [TBL] [Abstract][Full Text] [Related]
9. Prospective phase II clinical trial of autologous haematopoietic stem cell transplant for treatment refractory multiple sclerosis. Moore JJ; Massey JC; Ford CD; Khoo ML; Zaunders JJ; Hendrawan K; Barnett Y; Barnett MH; Kyle KA; Zivadinov R; Ma KC; Milliken ST; Sutton IJ; Ma DDF J Neurol Neurosurg Psychiatry; 2019 May; 90(5):514-521. PubMed ID: 30538138 [TBL] [Abstract][Full Text] [Related]
10. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
11. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial. Krapf H; Morrissey SP; Zenker O; Zwingers T; Gonsette R; Hartung HP; Neurology; 2005 Sep; 65(5):690-5. PubMed ID: 16157900 [TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of autologous peripheral blood stem cell transplantation in opticospinal and conventional forms of secondary progressive multiple sclerosis in a Chinese population. Xu J; Ji BX; Su L; Dong HQ; Sun WL; Wan SG; Liu YO; Zhang P; Liu CY Ann Hematol; 2011 Mar; 90(3):343-8. PubMed ID: 20872003 [TBL] [Abstract][Full Text] [Related]
13. MRI and CSF oligoclonal bands after autologous hematopoietic stem cell transplantation in MS. Saiz A; Carreras E; Berenguer J; Yagüe J; Martínez C; Marín P; Rovira M; Pujol T; Arbizu T; Graus F Neurology; 2001 Apr; 56(8):1084-9. PubMed ID: 11320183 [TBL] [Abstract][Full Text] [Related]